Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

ObjectiveThis study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies patients including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutières syndrome (AGS), and spo...

Full description

Bibliographic Details
Main Authors: Wendao Li, Wei Wang, Linqing Zhong, Lijuan Gou, Changyan Wang, Jingran Ma, Meiying Quan, Shan Jian, Xiaoyan Tang, Yu Zhang, Lin Wang, Mingsheng Ma, Hongmei Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
type I interferonopathies
autoinflammatory disorders
Janus kinase inhibitors
ruxolitinib
tofacitinib
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.825367/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.825367/full

Similar Items